OTCMKTS:RSLSD

ReShape Lifesciences Competitors

Add
Compare
Today's Range N/A
50-Day Range
$5.37
MA: $5.37
$5.37
52-Week Range N/A
Volume6,500 shs
Average Volume1,362 shs
Market Capitalization$1.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03

Competitors

ReShape Lifesciences (OTCMKTS:RSLSD) Vs. NIMU, NXNN, ARDMQ, MAGAA, ECTE, and SCIE

Should you be buying RSLSD stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to ReShape Lifesciences, including Non-Invasive Monitoring Systems (NIMU), Nexeon MedSystems (NXNN), Aradigm (ARDMQ), Magna-Lab (MAGAA), Echo Therapeutics (ECTE), and SpectraScience (SCIE).

ReShape Lifesciences (OTCMKTS:RSLSD) and Non-Invasive Monitoring Systems (OTCMKTS:NIMU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and price targets for ReShape Lifesciences and Non-Invasive Monitoring Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences0000N/A
Non-Invasive Monitoring Systems0000N/A

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares ReShape Lifesciences and Non-Invasive Monitoring Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-668.58%-163.22%-52.10%
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%

Earnings and Valuation

This table compares ReShape Lifesciences and Non-Invasive Monitoring Systems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A

Non-Invasive Monitoring Systems has lower revenue, but higher earnings than ReShape Lifesciences.

Summary

ReShape Lifesciences beats Non-Invasive Monitoring Systems on 4 of the 6 factors compared between the two stocks.

Nexeon MedSystems (OTCMKTS:NXNN) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, meaning that its share price is 1,171% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Profitability

This table compares Nexeon MedSystems and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nexeon MedSystemsN/AN/AN/A
ReShape Lifesciences-668.58%-163.22%-52.10%

Analyst Recommendations

This is a breakdown of current recommendations for Nexeon MedSystems and ReShape Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nexeon MedSystems0000N/A
ReShape Lifesciences0000N/A

Earnings & Valuation

This table compares Nexeon MedSystems and ReShape Lifesciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexeon MedSystemsN/AN/AN/AN/AN/A
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A

Nexeon MedSystems has higher earnings, but lower revenue than ReShape Lifesciences.

Summary

Nexeon MedSystems beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLSD) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.

Profitability

This table compares ReShape Lifesciences and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-668.58%-163.22%-52.10%
AradigmN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for ReShape Lifesciences and Aradigm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences0000N/A
Aradigm0000N/A

Earnings & Valuation

This table compares ReShape Lifesciences and Aradigm's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A
AradigmN/AN/AN/AN/AN/A

Aradigm has lower revenue, but higher earnings than ReShape Lifesciences.

Summary

Aradigm beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

Magna-Lab (OTCMKTS:MAGAA) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Magna-Lab and ReShape Lifesciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magna-Lab0000N/A
ReShape Lifesciences0000N/A

Earnings & Valuation

This table compares Magna-Lab and ReShape Lifesciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magna-LabN/AN/A$-130,000.00N/AN/A
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A

Magna-Lab has higher earnings, but lower revenue than ReShape Lifesciences.

Profitability

This table compares Magna-Lab and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magna-LabN/A-12.32%42,399.99%
ReShape Lifesciences-668.58%-163.22%-52.10%

Volatility & Risk

Magna-Lab has a beta of 5.2, indicating that its stock price is 420% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Summary

Magna-Lab beats ReShape Lifesciences on 5 of the 6 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLSD) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Valuation & Earnings

This table compares ReShape Lifesciences and Echo Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Echo Therapeutics has lower revenue, but higher earnings than ReShape Lifesciences.

Analyst Ratings

This is a summary of recent ratings and price targets for ReShape Lifesciences and Echo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences0000N/A
Echo Therapeutics0000N/A

Profitability

This table compares ReShape Lifesciences and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-668.58%-163.22%-52.10%
Echo TherapeuticsN/AN/AN/A

Summary

Echo Therapeutics beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLSD) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Valuation and Earnings

This table compares ReShape Lifesciences and SpectraScience's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A
SpectraScienceN/AN/AN/AN/AN/A

SpectraScience has lower revenue, but higher earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and SpectraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-668.58%-163.22%-52.10%
SpectraScienceN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ReShape Lifesciences and SpectraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences0000N/A
SpectraScience0000N/A

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

SpectraScience beats ReShape Lifesciences on 3 of the 5 factors compared between the two stocks.


ReShape Lifesciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.49 millionN/A0.00Upcoming Earnings
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
MAGAA
Magna-Lab
0.7$0.43flat$507,000.00N/A2.39Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.02flat$234,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$177,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.00flat$166,000.00N/A0.00News Coverage
Gap Up
ULGX
Urologix
0.6$0.01flat$153,000.00N/A0.00Gap Down
AKSY
Aksys
0.0$0.05flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40flat$0.00$9.40 million-6.67
HRTT
Heart Tronics
0.0$0.02flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00Gap Up
PECN
Photoelectron
0.2$0.00flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.